Our work demonstrates that the Tim-3/galectin-9 signaling pathway mediates T-cell senescence in HBV-associated HCC. The data suggest that this pathway could be an immunotherapeutic target in patients with HBV-associated HCC.
No takes yet. Share an insight, caveat, or question.
Li et al. (2012) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: